Exosomes/Autologous Conditioned Serum for Mild Cartilage Damage (Osteoarthritis I-II) | Avancell Joint Vienna, Austria

Avancell Joint in Vienna offers cutting-edge treatment using exosomes/autologous conditioned serum for individuals with mild cartilage damage, typically classified as osteoarthritis I-II with a slight inflammatory reaction or mild joint effusion. This advanced therapy harnesses the body's natural healing mechanisms to regenerate and repair damaged cartilage, offering renewed hope for those suffering from joint pain and limited mobility. The procedure involves extracting and concentrating exosomes or autologous conditioned serum from the patient's blood from 20 to 50 milliliters. Exosomes are tiny extracellular vesicles crucial in cell-to-cell communication and tissue regeneration. Autologous conditioned serum (ACS) is derived from the patient's blood and enriched with various growth factors and cytokines promoting healing. In treating mild cartilage damage (osteoarthritis I-II), exosomes and ACS stimulate the body's natural repair processes within the affected joint. These bioactive substances are injected directly into the joint space, exerting their regenerative effects, promoting cartilage repair, reducing inflammation, and alleviating pain. Vienna Avancell Joint boasts state-of-the-art facilities and a team of experienced specialists dedicated to providing personalized care and innovative solutions for joint health. The purchase of additional services, such as receiving an MRI prescription or a free second opinion on previous diagnoses, as well as inclusion in the Avancell rehabilitation protocol, follow-up examinations, and remote virtual rehabilitation and physical therapy, can be beneficial for patients, as it allows for a more complete and adequate recovery after the procedure. These services assist in tracking treatment progress and ensuring optimal patient rehabilitation outcomes. Exosomes and ACS offer several advantages, including minimal risk of adverse reactions or rejection since they are derived from the patient's tissues. Additionally, they provide a targeted and tailored approach to joint regeneration, addressing the underlying causes of cartilage damage. Overall, exosomes and ACS represent a promising option for individuals with mild cartilage damage, offering the potential for improved joint function and symptom relief without the need for invasive procedures or prolonged recovery times. With this revolutionary approach, patients can experience improved joint function, reduced pain, and enhanced quality of life, all within a comfortable and welcoming clinical environment. Avancell Joint is committed to delivering exceptional outcomes and empowering individuals to regain mobility and live fully.